MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss and
comprehensive loss
-$8,985K
Operating loss
-$7,821K
Other expense direct
listing offering costs
$1,164K
Total operating
expenses
$7,821K
Research and development
expenses
$6,266K
General and
administrative expenses
$1,555K
Back
Back
Income Statement
source: myfinsight.com
Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)